Subgroup analyses of etanercept in pediatric patients with psoriasis.
Paller
Amy S
AS
Eichenfield
Lawrence F
LF
Langley
Richard G
RG
Leonardi
Craig L
CL
Siegfried
Elaine C
EC
Creamer
Kara
K
Kricorian
Gregory
G
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept